Cargando…

Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model

Dalbavancin is a new semisynthetic lipoglycopeptide with improved antimicrobial activity against various gram-positive pathogens. It demonstrates an extensive plasma half-life which permits outpatient parenteral antimicrobial therapy with weekly intervals and might therefore be an excellent treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kussmann, Manuel, Obermueller, Markus, Berndl, Florian, Reischer, Veronika, Veletzky, Luzia, Burgmann, Heinz, Poeppl, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018549/ https://www.ncbi.nlm.nih.gov/pubmed/29941909 http://dx.doi.org/10.1038/s41598-018-28006-8

Ejemplares similares

Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis
por: Kussmann, Manuel, et al.
Publicado: (2018)

Different Types of Coagulase Are Associated With 28-Day Mortality in Patients With Staphylococcus aureus Bloodstream Infections
por: Karer, Matthias, et al.
Publicado: (2020)

Influence of different peritoneal dialysis fluids on the in vitro activity of fosfomycin against Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa
por: Kussmann, Manuel, et al.
Publicado: (2018)

Dalbavancin Use for the Treatment of Methicillin-resistant Staphylococcus aureus Pneumonia
por: Barber, Katie E., et al.
Publicado: (2017)

Dalbavancin Boosts the Ability of Neutrophils to Fight Methicillin-Resistant Staphylococcus aureus
por: Scutera, Sara, et al.
Publicado: (2023)

Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE)
por: Knafl, D., et al.
Publicado: (2016)

Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report
por: Almangour, Thamer A., et al.
Publicado: (2017)

In vitro activity of immunosuppressive drugs against Plasmodium falciparum
por: Veletzky, Luzia, et al.
Publicado: (2014)

Synergistic Effect of Cefazolin Plus Fosfomycin Against Staphylococcus aureus in vitro and in vivo in an Experimental Galleria mellonella Model
por: Kussmann, Manuel, et al.
Publicado: (2021)

Dalbavancin is thermally stable at clinically relevant temperatures against methicillin-sensitive Staphylococcus Aureus
por: Hoyt, Aaron K., et al.
Publicado: (2023)

Resolution of Staphylococcus aureus (methicillin-resistant Staphylococcus aureus) osteomyelitis by oral linezolid
por: Gomes, PN, et al.
Publicado: (2003)

Dalbavancin treatment of methicillin-susceptible Staphylococcus aureus pyomyositis with torpid evolution: a case report
por: Otero, Judith Álvarez, et al.
Publicado: (2019)

Dalbavancin for Staphylococcus aureus Bacteremia: Are We There Yet?
por: Mahatanan, Rattanaporn, et al.
Publicado: (2023)

Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis
por: Karau, Melissa J., et al.
Publicado: (2022)

1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus
por: Streifel, Amber C, et al.
Publicado: (2020)

Treatment of Methicillin-resistant Staphylococcus aureus experimental Osteomyelitis with bone-targeted Vancomycin
por: Karau, Melissa J, et al.
Publicado: (2013)

Successful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin
por: Loupa, Chariclia V., et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Dalbavancin Alone and in Combination with Ceftaroline against Methicillin-Resistant Strains (MRSA) of Staphylococcus aureus
por: Kebriaei, Razieh, et al.
Publicado: (2017)

Dalbavancin was effective and safe after one year of treatment in a complicated osteoarticular infection caused by methicillin-resistant Staphylococcus aureus
por: Matesanz, Mayra, et al.
Publicado: (2021)

Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant Staphylococcus aureus: A Retrospective Single-Centre Experience
por: Mazzitelli, Maria, et al.
Publicado: (2022)

Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions
por: Kussmann, Manuel, et al.
Publicado: (2019)

Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistant Staphylococcus aureus implant-associated osteomyelitis
por: Karau, Melissa, et al.
Publicado: (2022)

Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

In vitro additive effects of dalbavancin and rifampicin against biofilm of Staphylococcus aureus
por: Jacob, Benjamin, et al.
Publicado: (2021)

Comparison of clinical features and outcomes of staphylococcus aureus vertebral osteomyelitis caused by methicillin-resistant and methicillin-sensitive strains
por: Inoue, Shinichi, et al.
Publicado: (2013)

Hemipelvic osteomyelitis in a hemodialysis patient associated with methicillin-resistant Staphylococcus aureus bacteremia
por: Patzkowski, Jeanne C, et al.
Publicado: (2008)

Methicillin resistant Staphylococcus aureus causing osteomyelitis in a tertiary hospital, Mwanza, Tanzania
por: Silago, Vitus, et al.
Publicado: (2020)

Role of Extracellular DNA in Dalbavancin Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms in Patients with Skin and Soft Tissue Infections
por: Sivori, Francesca, et al.
Publicado: (2022)

Compatibility of aztreonam in four commercial peritoneal dialysis fluids
por: Tobudic, Selma, et al.
Publicado: (2020)

Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for Staphylococcus aureus Bloodstream Infections
por: Molina, Kyle C, et al.
Publicado: (2022)

Methicillin-resistant Staphylococcus aureus mandibular osteomyelitis in an extremely low birth weight preterm infant
por: Martini, Silvia, et al.
Publicado: (2015)

Declining Prevalence of Methicillin-Resistant Staphylococcus aureus Septic Arthritis and Osteomyelitis in Children: Implications for Treatment
por: Weiss, Lindsay, et al.
Publicado: (2020)

In Vitro Activities of Ceftobiprole, Dalbavancin, Tedizolid and Comparators against Clinical Isolates of Methicillin-Resistant Staphylococcus aureus Associated with Skin and Soft Tissue Infections
por: Maraki, Sofia, et al.
Publicado: (2023)

2129. When Is Methicillin-resistant Staphylococcus aureus not Methicillin-resistant Staphylococcus aureus?
por: Gitman, Melissa R, et al.
Publicado: (2019)

Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population
por: Bryson-Cahn, Chloe, et al.
Publicado: (2019)

2255. The Use of Dalbavancin for Staphylococcus aureus Bacteremia in Persons Who Inject Drugs (PWID)
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

In Vitro Activity of Dalbavancin against Refractory Multidrug-Resistant (MDR) Staphylococcus aureus Isolates
por: Bongiorno, Dafne, et al.
Publicado: (2020)

Panton–Valentine Leukocidin Enhances the Severity of Community-Associated Methicillin-Resistant Staphylococcus aureus Rabbit Osteomyelitis
por: Crémieux, Anne-Claude, et al.
Publicado: (2009)

Osteomyelitis due to methicillin-resistant Staphylococcus aureus successfully treated by an oral combination of minocycline and trimethoprim–sulfamethoxazole
por: Sato, Kojiro, et al.
Publicado: (2019)

Primary Sternal Osteomyelitis Caused by Methicillin-Sensitive Staphylococcus aureus: A Diagnosis Rare in Healthy Adults
por: Araújo, Tiago, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u2i4531l9143l9qnefo10k7o4s